Supernus to Present at Two Investor Conferences ROCKVILLE, Md., May 20, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in May and June 2013: Deutche Bank Conference: Presentation Date: Thursday, May 30th Time: 2:50 PM ET Place: The Westin Boston Waterfront Hotel- Boston, MA Jefferies Conference: Presentation Date: Tuesday, June 4th Time: 10:00 AM ET Place: Grand Hyatt New York- New York, NY About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.The Company has one approved product for epilepsy, Oxtellar XR^TM (extended release oxcarbazepine), and one tentatively approved product for epilepsy, Trokendi XR^TM (extended release topiramate).The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD. CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591
Supernus to Present at Two Investor Conferences
Press spacebar to pause and continue. Press esc to stop.